Gil Alejandro Garrido Echeverria

Gil Alejandro Garrido Echeverria

Auto-generated profile, based on publicly available information

Gil Alejandro Garrido Echeverria

ISSSTE

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
CACristian Arturo Abia-Meashima
Cristian Arturo Abia-Meashima
GEGil Alejandro Garrido Echeverria
Gil Alejandro Garrido Echeverria
MMMaría Cristina Martínez Mazón
María Cristina Martínez Mazón
CHCristian David Castro Hernandez
Cristian David Castro Hernandez
FRFélix Anel Badillo Rivera
Félix Anel Badillo Rivera
LHLuis Alberto Erosa-De Haro
Luis Alberto Erosa-De Haro
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent metabolic disorder characterized by substantial clinical heterogeneity and frequent association with obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, visceral adiposity, and alterations in body composition. This study analyzed the principal clinical phenotypes of MASLD and their relationship with personalized nutritional interventions through a structured analytical review of clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and observational studies. The evidence showed marked differences in disease prevalence and metabolic characteristics across lean, overweight, obese, and diabetic populations. Sustained weight loss was associated with progressive hepatic improvement, with reductions of approximately 5% linked to decreased liver fat, 7–10% to improvement in inflammatory activity, and reductions of 10% or greater to greater probability of fibrosis improvement. Dietary quality was also relevant independently of absolute weight reduction, particularly through Mediterranean-style patterns, reduced intake of added sugars and ultra-processed foods, and replacement of saturated fats with unsaturated sources. Lean MASLD represented a distinct phenotype in which metabolic dysfunction may persist despite normal body mass index, requiring greater emphasis on body composition, visceral adiposity, physical activity, and preservation of lean mass rather than aggressive caloric restriction. Overall, the findings support a phenotype-oriented model of nutritional management in which common evidence-based lifestyle principles are maintained while the intensity and priority of specific interventions are adapted to individual metabolic, hepatic, anthropometric, and behavioral characteristics. Further prospective studies are required to determine whether personalized nutritional strategies improve long-term fibrosis progression, cardiovascular outcomes, liver-related complications, and mortality.

30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
CLCristobal Washigton Franco Lucas
Cristobal Washigton Franco Lucas
DADayanna Estefania Fernández Astudillo
Dayanna Estefania Fernández Astudillo
ARAlberto Macías Rodríguez
Alberto Macías Rodríguez
FRFélix Anel Badillo Rivera
Félix Anel Badillo Rivera
MCMelkin Andrés Triana Castro
Melkin Andrés Triana Castro
SPSantiago Andres Trujillo Perez
Santiago Andres Trujillo Perez
Cardiorenal syndrome represents a complex clinical condition resulting from bidirectional interactions between cardiac and renal dysfunction and is particularly relevant in patients with multimorbidity, in whom heart failure, chronic kidney disease, diabetes mellitus, hypertension, obesity, and vascular disease frequently coexist. This study analyzed current evidence regarding emerging biomarkers, prognostic stratification, and integrated therapeutic approaches in adult patients with cardiorenal syndrome and multimorbidity. A structured integrative review based on the Scientific Method was conducted using contemporary clinical guidelines, scientific statements, randomized controlled trials, observational studies, and biomarker investigations. The analysis focused on conventional parameters and emerging biomarkers associated with glomerular filtration, tubular injury, myocardial stress, inflammation, and fibrosis. Cystatin C showed its greatest relevance as a complementary marker of glomerular function, while NGAL and KIM-1 were predominantly associated with tubular injury. NT-proBNP was mainly related to myocardial stress and congestion, whereas sST2 and galectin-3 provided additional information regarding inflammatory and fibrotic remodeling. Prognostic assessment demonstrated that declining estimated glomerular filtration rate, increased albuminuria, persistent congestion, recurrent heart failure decompensation, biomarker abnormalities, and greater multimorbidity burden were consistently associated with adverse cardiorenal outcomes. Therapeutic evidence from major randomized trials showed that sodium–glucose cotransporter-2 inhibitors significantly reduced major kidney and cardiovascular events across broad chronic kidney disease populations, while finerenone demonstrated complementary renal and cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease. The findings support a transition from isolated organ-based evaluation toward a multidimensional cardiorenal framework integrating renal function, cardiovascular status, metabolic disease, biomarker profiles, and therapeutic response. Emerging biomarkers may improve biological phenotyping but should currently complement rather than replace established clinical variables. Integrated, multidisciplinary management involving internal medicine, cardiology, and nephrology may provide a more coherent approach to risk stratification and individualized treatment in patients with complex cardiorenal disease.